Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8442219 | 0.85 | CYP2C19 (0.40) | ACEKMT2ATSHR | |
| SCHEMBL8374671 | 0.85 | CYP2C19 (0.40) | ACEKMT2ATSHR | |
| SCHEMBL8438654 | 0.85 | CYP2C19 (0.40) | ACEKMT2ATSHR | |
| SCHEMBL8439708 | 0.83 | SIGMAR1 (0.51) | ACEKMT2A | |
| SCHEMBL8439648 | 0.82 | ALDH1A1 (0.47) | MAPTSMN1; SMN2ACEMAPK1 | |
| SCHEMBL8439425 | 0.81 | HTT (0.50) | SMN1; SMN2MAPK1GAAMEN1KMT2A | |
| SCHEMBL8441249 | 0.80 | HMOX1 (0.41) | ACE | |
| SCHEMBL8720293 | 0.79 | SNCA (0.36) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8102631 | 0.79 | APP (0.41) | — | |
| SCHEMBL8441617 | 0.79 | TP53 (0.46) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996019451-A1 | SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-27 | — | — | WO | claimed |
| US-5990102-A | Substituted azetidin-2-ones for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-23 | — | — | US | disclosed |
| EP-0900199-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1999-03-10 | — | — | EP | disclosed |
| CN-1197452-A | Azetidinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 1998-10-28 | — | — | CN | disclosed |
| EP-0840725-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997041099-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-11-06 | — | — | WO | disclosed |
| EP-0799200-A1 | SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1997002242-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-01-23 | — | — | WO | disclosed |
| WO-1996019451-A1 | SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-27 | — | — | WO | disclosed |